5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.70▲ | 1.69▲ | 1.68▲ | 1.70▲ | 1.65▲ |
MA10 | 1.68▲ | 1.67▲ | 1.67▲ | 1.71▲ | 1.41▲ |
MA20 | 1.67▲ | 1.67▲ | 1.69▲ | 1.60▲ | 1.52▲ |
MA50 | 1.67▲ | 1.72▼ | 1.72▼ | 1.28▲ | 1.61▲ |
MA100 | 1.71▲ | 1.71▼ | 1.66▲ | 1.59▲ | 1.88▼ |
MA200 | 1.73▼ | 1.62▲ | 1.47▲ | 1.65▲ | 3.68▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.005▲ | 0.007▲ | 0.003▲ | -0.005▼ | 0.057▲ |
RSI | 65.023▲ | 57.846▲ | 54.717▲ | 62.012▲ | 53.374▲ |
STOCH | 88.889▲ | 78.333 | 55.833 | 53.055 | 75.470 |
WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -22.892▲ | -42.106 |
CCI | 175.000▲ | 194.265▲ | 132.668▲ | 16.995 | 76.588 |
Monday, June 16, 2025 05:00 AM
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete Response Letter (CRL) regarding its New Drug ...
|
Wednesday, May 28, 2025 04:59 AM
MONTREAL AND CHARLOTTE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller ...
|
Thursday, May 22, 2025 09:00 AM
Milestone Pharmaceuticals (MIST) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/06/25 | 1.655 | 1.71 | 1.65 | 1.71 | 304,503 |
13/06/25 | 1.64 | 1.69 | 1.64 | 1.65 | 479,200 |
12/06/25 | 1.69 | 1.735 | 1.66 | 1.68 | 411,200 |
11/06/25 | 1.76 | 1.77 | 1.71 | 1.72 | 520,500 |
10/06/25 | 1.77 | 1.78 | 1.75 | 1.75 | 472,714 |
09/06/25 | 1.77 | 1.805 | 1.71 | 1.75 | 771,825 |
06/06/25 | 1.76 | 1.77 | 1.70 | 1.73 | 535,000 |
05/06/25 | 1.70 | 1.76 | 1.6406 | 1.74 | 780,269 |
04/06/25 | 1.68 | 1.7158 | 1.64 | 1.65 | 574,667 |
03/06/25 | 1.74 | 1.75 | 1.66 | 1.69 | 731,964 |
|
|
||||
|
|
||||
|
|